|
GB9823103D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
WO2002009713A2
(de)
|
2000-08-01 |
2002-02-07 |
Bayer Aktiengesellschaft |
Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
|
|
CN1481244A
(zh)
*
|
2000-12-19 |
2004-03-10 |
Ĭ��ר���ɷ�����˾ |
含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
|
|
DE10064105A1
(de)
|
2000-12-21 |
2002-06-27 |
Bayer Ag |
Neue Substituierte Imidazotriazinone
|
|
CA2437085A1
(en)
*
|
2001-02-02 |
2002-08-15 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
|
|
KR100393160B1
(ko)
*
|
2001-06-14 |
2003-07-31 |
한국과학기술연구원 |
신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
|
|
US6479493B1
(en)
|
2001-08-23 |
2002-11-12 |
Cell Pathways, Inc. |
Methods for treatment of type I diabetes
|
|
WO2003072541A2
(en)
*
|
2001-09-27 |
2003-09-04 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
FR2842809A1
(fr)
*
|
2002-07-26 |
2004-01-30 |
Greenpharma Sas |
NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
|
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
DE10238723A1
(de)
*
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
|
DE10238724A1
(de)
*
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
|
CN100397023C
(zh)
*
|
2003-01-04 |
2008-06-25 |
胡云北 |
黄磷废渣载热量及反应尾气发热量的回收与综合利用方法
|
|
EP1601675A1
(en)
*
|
2003-03-04 |
2005-12-07 |
ALTANA Pharma AG |
Purin-6-one-derivatives
|
|
DE10320785A1
(de)
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Arylmethyl-substituierte Pyrazolopyrimidine
|
|
US8044060B2
(en)
|
2003-05-09 |
2011-10-25 |
Boehringer Ingelheim International Gmbh |
6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
|
|
DE102004004142A1
(de)
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
|
|
DE10328479A1
(de)
|
2003-06-25 |
2005-01-13 |
Bayer Ag |
6-Arylamino-5-cyano-4-pyrimidinone
|
|
JP2007504117A
(ja)
*
|
2003-08-28 |
2007-03-01 |
アルタナ ファルマ アクチエンゲゼルシャフト |
肺サーファクタントとｐｄｅ２阻害剤とを含有する組成物
|
|
DE102004001873A1
(de)
|
2004-01-14 |
2005-09-29 |
Bayer Healthcare Ag |
Cyanopyrimidinone
|
|
EP1720878A1
(en)
*
|
2004-02-27 |
2006-11-15 |
F.Hoffmann-La Roche Ag |
Heteroaryl-fused pyrazolo derivatives
|
|
CN101397299B
(zh)
*
|
2007-09-29 |
2011-11-16 |
温州大学 |
一种吡唑[3,4-d]嘧啶酮的合成方法
|
|
PE20091211A1
(es)
|
2007-11-30 |
2009-09-14 |
Boehringer Ingelheim Int |
Derivados de pirazolopirimidina como moduladores de pde9a
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
AP2011005672A0
(en)
|
2008-09-08 |
2011-04-30 |
Boehringer Ingelheim Int |
Pyrazolopyrimidines and their use for the treatment of CNS disorders.
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
EP2414344A1
(en)
|
2009-03-31 |
2012-02-08 |
ArQule, Inc. |
Substituted indolo-pyridinone compounds
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
HUE033378T2
(en)
|
2010-08-12 |
2017-11-28 |
Boehringer Ingelheim Int |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
US20130040971A1
(en)
|
2011-02-14 |
2013-02-14 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
WO2013030713A1
(en)
|
2011-08-31 |
2013-03-07 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
|
|
JO3407B1
(ar)
|
2012-05-31 |
2019-10-20 |
Eisai R&D Man Co Ltd |
مركبات رباعي هيدرو بيرازولو بيريميدين
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
BR112015019276A2
(pt)
|
2013-02-19 |
2017-07-18 |
Pfizer |
compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
|
|
WO2015049616A1
(en)
|
2013-10-04 |
2015-04-09 |
Pfizer Inc. |
Novel bicyclic pyridinones as gamma-secretase modulators
|
|
WO2015150957A1
(en)
|
2014-04-01 |
2015-10-08 |
Pfizer Inc. |
Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
|
US10131669B2
(en)
|
2014-07-24 |
2018-11-20 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
|
EA031201B1
(ru)
|
2014-08-06 |
2018-11-30 |
Пфайзер Инк. |
Соединения имидазопиридазина
|
|
WO2016125048A1
(en)
|
2015-02-03 |
2016-08-11 |
Pfizer Inc. |
Novel cyclopropabenzofuranyl pyridopyrazinediones
|
|
JO3627B1
(ar)
|
2015-04-30 |
2020-08-27 |
H Lundbeck As |
إيميدازو بيرازينونات على هيئة مثبطات pde1
|
|
WO2016179059A1
(en)
*
|
2015-05-05 |
2016-11-10 |
Merck Sharp & Dohme Corp. |
Heteroaryl-pyrimidinone compounds as pde2 inhibitors
|
|
ES2924371T3
(es)
|
2015-06-17 |
2022-10-06 |
Pfizer |
Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
|
|
BR112018015191B1
(pt)
|
2016-02-23 |
2023-10-17 |
Pfizer Inc |
Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende
|
|
TWI729109B
(zh)
|
2016-04-12 |
2021-06-01 |
丹麥商Ｈ 朗德貝克公司 |
作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
|
|
DK3478679T3
(da)
|
2016-07-01 |
2021-06-21 |
Pfizer |
5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
|
|
EP3529250B1
(en)
*
|
2016-10-18 |
2023-12-06 |
H. Lundbeck A/S |
Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
|
|
PT3532064T
(pt)
|
2016-10-28 |
2020-09-03 |
H Lundbeck As |
Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
|
|
MA46621A
(fr)
|
2016-10-28 |
2021-06-02 |
H Lundbeck As |
Traitements combinés comprenant l'administration d'imidazopyrazinones
|
|
WO2018125810A1
(en)
|
2016-12-28 |
2018-07-05 |
Dart Neuroscience, Llc |
Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
|
|
RU2019144010A
(ru)
|
2017-06-08 |
2021-07-13 |
Мерк Шарп И Доум Корп. |
Пиразолопиримидиновые ингибиторы pde9
|
|
FI3642202T3
(fi)
|
2017-06-22 |
2023-03-01 |
|
Dihydro-pyrrolo-pyridiinijohdannaisia
|
|
CN111655695B
(zh)
|
2017-11-27 |
2025-05-27 |
达特神经科学有限公司 |
作为pde1抑制剂的取代的呋喃并嘧啶化合物
|
|
CA3094366A1
(en)
|
2018-03-23 |
2019-09-26 |
Pfizer Inc. |
Piperazine azaspiro derivatives
|
|
USD1029414S1
(en)
*
|
2021-01-19 |
2024-05-28 |
Averia Electronics, Inc. |
Wearable light emitting module with a removable band
|
|
USD1021287S1
(en)
*
|
2021-01-19 |
2024-04-02 |
Averia Electronics, Inc. |
Wearable light emitting module with a removable band
|
|
EP4297868A4
(en)
|
2021-02-23 |
2025-01-08 |
Hoth Therapeutics, Inc. |
USE OF APREPITANT TO TREAT ALZHEIMER'S
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|